Skip to main content

Table 5 Summary of the performances of K13 bMx prototype according to the origin of the samples (all samples, N = 590; samples collected from P. falciparum symptomatic patients, N = 544; and samples collected from the P. falciparum asymptomatic individuals, N = 46)

From: A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants

Samples from Performances K13 mutants K13 wild-type
C580Y F446I R539T Y493H
All samples Sensitivity (CI 95%) 90.2%
(85.9–93.6)
95.8%
(88.1–99.1)
95.2%
(76.1–99.9)
90.0%
(68.3–98.8)
94.1%
(90.2–96.8)
Specificity (CI 95%) 99.4%
(97.6–99.9)
98.0%
(96.2–99.0)
100%
(99.4–100)
99.8%
(99.0–99.9)
92.4%
(89.2–94.9)
AUC
(CI 95%)
0.948
(0.927–0.965)
0.968
(0.951–0.981)
0.976
(0.961–0.987)
0.949
(0.928–0.965)
0.933
(0.909–0.952)
PPV
(CI 95%)
99.1%
(96.6–99.8)
86.1%
(77.5–91.7)
100% 94.7%
(71.6–99.2)
88.2%
(83.9–91.4)
NPV
(CI 95%)
93.0%
(90.1–95.1)
99.4%
(98.2–99.8)
99.8%
(98.9–99.9)
99.7%
(98.7–99.9)
96.3%
(93.9–97.8)
P. falciparum symptomatic patients Sensitivity (CI 95%) 95.8%
(92.1–98.0)
95.8%
(88.1–99.1)
95.2%
(76.2–99.9)
90.0%
(68.3–98.8)
94.0%
(90.1–96.8)
Specificity (CI 95%) 99.4%
(97.8–99.9)
97.6%
(95.7–98.8)
100%
(99.3–100)
99.8%
(98.9–99.9)
96.0%
(93.3–97.9)
AUC
(CI 95%)
0.976
(0.958–0.987)
0.967
(0.949–0.981)
0.976
(0.960–0.987)
0.949
(0.927–0.966)
0.950
(0.929–0.967)
PPV
(CI 95%)
99.0%
(96.2–99.8)
86.1%
(77.5–91.7)
100% 94.7%
(71.6–99.2)
94.1%
(90.3–96.4)
NPV
(CI 95%)
97.3%
(95.1–98.6)
99.3%
(98.1–99.8)
99.8%
(98.7–99.9)
99.6%
(98.5–99.9)
96.0%
(93.4–97.6)
P. falciparum asymptomatic individuals Sensitivity (CI 95%) 62.8%
(46.7–77.0)
    100%
(29.2–100)
Specificity (CI 95%)     65.1%
(49.1–79.0)
AUC
(CI 95%)
0.314
(0.185–0.468)
    0.826
(0.699–0.915)
PPV
(CI 95%)
90.0%
(87.7–91.9)
    16.7%
(11.7–23.1)
NPV
(CI 95%)
    100%
  1. AUC areas under the ROC curves, PPV positive predictive value, NPV negative predictive value, CI 95% confidence intervals 95%